M. Solh

发表

The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation.

M. Solh, D. Speckhart, S. Solomon, 2020, Blood advances.

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy

D. Weisdorf, S. Yohe, M. Solh, 2014, American journal of hematology.

Survival following allogeneic transplant in patients with myelofibrosis.

N. Kröger, M. Arcasoy, S. Verstovsek, 2020, Blood advances.

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chimeric Antigen Receptor T-Cells: The Future Is Now

M. Solh, R. Sehgal, W. Mchayleh, 2019, Journal of clinical medicine.

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

M. Aljurf, J. Szer, R. Gale, 2019, Blood advances.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

M. Norkin, H. Nakasone, M. Aljurf, 2018, Blood advances.

Extramedullary acute myelogenous leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Blood reviews.

Pulmonary Complications of Chronic Lymphocytic Leukemia

M. Solh, P. Wadhwa, 2011 .

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

P. Hari, J. Zaucha, M. Krem, 2020, Cancer.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

R. Vij, W. Wood, M. Aljurf, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

M. Aljurf, R. Gale, K. Ballen, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.

K. Ballen, O. Ringdén, D. Rizzieri, 2020, Biology of Blood and Marrow Transplantation.

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia & lymphoma.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

R. Gale, H. Khoury, U. Popat, 2018, Blood advances.

Late-Onset Noninfectious Pulmonary Complications in Adult Allogeneic Hematopoietic Cell Transplant Recipients

D. Weisdorf, M. Solh, N. Majhail, 2011, Transplantation.

Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.

J. Wingard, T. Spitzer, B. Shaw, 2020, Blood advances.

Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma

A. Stathis, S. Liao, J. Boni, 2021, The AAPS Journal.

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

K. Ardeshna, M. Lunning, P. Caimi, 2021, Clinical Lymphoma Myeloma and Leukemia.

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

J. Radford, K. Ardeshna, O. O’Connor, 2019, Clinical Cancer Research.

The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)

R. Larson, F. Appelbaum, A. Belch, 2013, Leukemia & lymphoma.

Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis

M. Norkin, J. Wingard, J. Liesveld, 2020, Bone Marrow Transplantation.

Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

P. Hari, Shaji K. Kumar, R. Gale, 2020, Leukemia.

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States

S. Jagannath, R. Vij, P. Hari, 2020, Cancer.

Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

R. Vij, D. Lad, M. Perales, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

P. Hari, R. Kyle, Shaji K. Kumar, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

P. Hari, R. Kyle, Shaji K. Kumar, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Blood transfusions and pulmonary complications after hematopoietic cell transplantation

D. Weisdorf, J. McCullough, M. Solh, 2016, Transfusion.

The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

R. Vij, Lixin Yang, M. Aljurf, 2022, Haematologica.

Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and cellular therapy.

Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials

R. Neuwirth, D. Esseltine, S. de Vos, 2013, Leukemia & lymphoma.

Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma

S. Ouanounou, M. Solh, J. LaPorte, 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

J. Byrd, H. Tilly, A. Chanan-Khan, 2021, Blood.

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.

K. Ardeshna, C. Carlo-Stella, P. Caimi, 2020, Blood advances.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

A. Goldberg, M. Tallman, W. Stock, 2020, Leukemia research.

De novo CD3 negative hepatosplenic T-cell lymphoma: diagnostic challenges and pitfalls.

C. Chang, M. Solh, D. Ward, 2014, Archives of pathology & laboratory medicine.

Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.

Y. Liu, M. Aljurf, J. Szer, 2020, Blood advances.

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

E. Estey, B. Sandmaier, M. Krem, 2021, Bone Marrow Transplantation.

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach.

A. Copik, Dominic A. Colosimo, D. Altomare, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.

D. Weisdorf, M. Solh, S. Morgan, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

C. Craddock, V. Brown, C. Hourigan, 2022, Leukemia.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

M. Robin, G. Garcia-Manero, Z. DeFilipp, 2022, Transplantation and cellular therapy.

Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

M. Norkin, M. Aljurf, J. Wingard, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.

M. Solh, 2014, World journal of stem cells.

Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.

E. Leifer, H. Deeg, P. Westervelt, 2022, The Lancet. Haematology.

Safety and efficacy of rituximab-based first line treatment of chronic GVHD

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies

M. Solh, S. Solomon, A. Bashey, 2021, Advances in hematology.

Who is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Poster: ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis

J. Radford, K. Ardeshna, M. Lunning, 2021 .

LOTIS 2 FOLLOW-UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse.

D. Kaufman, D. Weisdorf, T. DeFor, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).

M. Solh, S. Solomon, A. Bashey, 2020, Leukemia research.

Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.

M. Tallman, R. Gale, M. Flowers, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

M. Krem, C. Hourigan, M. Aljurf, 2021, Blood advances.

Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.

A. Copik, Dean Anthony Lee, D. Altomare, 2016, Cytotherapy.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk In

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tumor Lysis Syndrome

M. Solh, J. Appel, 2008 .

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, M. Perales, R. Soiffer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation

M. Solh, S. Solomon, A. Bashey, 2016, Bone Marrow Transplantation.

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide

M. Solh, S. Solomon, A. Bashey, 2016, Advances in hematology.

Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.

J. Radford, P. Zinzani, K. Ardeshna, 2021, The Lancet. Oncology.

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

P. Riedell, F. Awan, M. Krem, 2021, JAMA oncology.

Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide.

Shannon R. McCurdy, M. Norkin, M. Perales, 2018, Blood advances.

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

R. Vij, M. Aljurf, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Processing the 5-mL umbilical cord blood unit with the use of an automated wash procedure.

M. Solh, J. Baumgartner, D. Lamontagne, 2015, Cytotherapy.

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

M. Aljurf, R. Gale, J. Pidala, 2020, Journal of Clinical Oncology.

Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?

J. Wagner, M. Perales, H. Lazarus, 2019, Haematologica.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

J. Radford, K. Ardeshna, O. O’Connor, 2018, Blood.

Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy.

M. Grunwald, O. Ringdén, H. Lazarus, 2021, Transplantation and cellular therapy.

Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options

M. Solh, Tia Solh, Ashley Botsford, 2015, Journal of blood medicine.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

R. Vij, M. Aljurf, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Receptor Characteristics of the Second Tumor in Synchronous versus Metachronous Breast Cancer

M. Solh, Hanadi Bu-Ali, V. Mittal, 2008, The American surgeon.

Synchronous versus metachronous breast cancer: Characteristics of the second tumor

M. Solh, V. Mittal, H. Ali, 2008 .

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

P. Hari, Shaji K. Kumar, R. Gale, 2021, Leukemia.

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A. Jakubowiak, S. Trudel, A. Lesokhin, 2020 .

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

Sonali M. Smith, R. Vij, W. Wood, 2019, Blood Cancer Journal.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

J. Mehta, M. Perales, N. Saba, 2019, Clinical Cancer Research.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

J. Vose, S. Montoto, Sonali M. Smith, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy

Anthony J Klappa, Y. Datta, M. Solh, 2011, American journal of hematology.

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2020 .

Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program

H. Kent Holland, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD)

M. Solh, S. Solomon, A. Bashey, 2021, Bone Marrow Transplantation.

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

M. Perales, Richard J. Jones, Y. Efebera, 2022, Blood.

Fludarabine and Total Body Irradiation Conditioning Prior to Ablative Haploidentical Transplantation: Long-term Safety and Efficacy.

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT

M. Solh, V. Reddy, Y. Khaled, 2013, Bone Marrow Transplantation.

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Shannon R. McCurdy, M. Perales, M. Horowitz, 2016 .

Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.

R. Vij, M. Aljurf, R. Gale, 2022, JAMA oncology.

Autoimmune Demyelinating Polyneuropathy as a Manifestation of Chronic Graft-versus-Host Disease after Adult Cord Blood Transplantation in a Patient with Chronic Lymphocytic Leukemia

M. Solh, Fredrick L. Hogan, 2014, Case reports in hematology.

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

F. Baron, M. Krem, C. Hourigan, 2021, Bone Marrow Transplantation.

Graft-versus-host disease prophylaxis

M. Solh, A. Bashey, 2017 .

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.

B. George, M. Grunwald, D. Weisdorf, 2021, Blood advances.

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

M. Aljurf, J. Szer, R. Gale, 2020 .

Graft-Versus-Host Disease (GVHD) after Post-Transplant Cyclophosphamide or Conventional GVHD Prophylaxis: Same Title, Different Song.

M. Solh, 2022, Transplantation and cellular therapy.

Differences in GVHD Characteristics Between Haploidentical Transplantation Using Post-Transplant Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.

M. Solh, S. Solomon, A. Bashey, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and Cellular Therapy.

A prognostic index for survival among mechanically ventilated hematopoietic cell transplant recipients.

R. Vogel, M. Solh, N. Majhail, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

J. Radford, K. Ardeshna, O. O’Connor, 2020, Blood.

Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation

J. Vose, P. Riedell, Sonali M. Smith, 2021, British journal of haematology.

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

J. Radford, K. Ardeshna, A. Stathis, 2022, Blood advances.

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

A. Jakubowiak, S. Trudel, M. Tomasson, 2021 .

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

A. Jakubowiak, S. Trudel, M. Tomasson, 2021, Blood.

Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study.

M. Aljurf, J. Szer, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma

M. Krem, Shaji K. Kumar, M. Qazilbash, 2022, Cancer.

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

M. Solh, S. Solomon, A. Bashey, 2015 .

High-dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and Cellular Therapy.

Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation

M. Norkin, R. Vij, M. Horowitz, 2018, Bone Marrow Transplantation.

ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Shaji K. Kumar, M. Aljurf, Y. Nieto, 2023, Blood advances.

Plasma cell CD20 expression: primary aberrant expression or receptor up-regulation

C. Chang, M. Solh, Y. Khaled, 2013, Leukemia & lymphoma.

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, S. Trudel, M. Tomasson, 2022, Blood.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

R. Varadhan, C. Huff, M. Perales, 2023, The New England journal of medicine.

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study.

J. Radford, K. Ardeshna, A. Stathis, 2023, Haematologica.

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, A. Stathis, 2019, Blood.

Plasma Cell CD20 Expression After Autologous Stem Cell Transplantation in Multiple Myeloma: Primary Aberrant Expression or Receptor up-Regulation

C. Chang, M. Solh, D. Ward, 2012 .

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

I. Yakoub-Agha, M. Aljurf, R. Gale, 2023, Blood advances.

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant

M. Solh, S. Solomon, A. Bashey, 2023, Blood advances.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

M. Perales, Richard J. Jones, J. Bolaños-Meade, 2023, The New England journal of medicine.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

U. Popat, M. Kalaycio, Z. DeFilipp, 2018, Blood advances.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

S. Trudel, M. Tomasson, S. Iida, 2023, Nature Medicine.

Tumor Lysis Syndrome

M. Cairo, P. Coccia, M. Solh, 2008 .

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

A. Jakubowiak, S. Trudel, M. Tomasson, 2023, Nature Medicine.

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

S. Kambhampati, H. Kantarjian, T. Kadia, 2018, Blood.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

M. Norkin, H. Nakasone, M. Aljurf, 2018, Blood advances.